SAN DIEGO / Aug 05, 2024 / Business Wire / Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided corporate updates.
“We are pleased to remain on track for our first commercial product launch of Kostaive® in Japan later this year,” said Joseph Payne, President & CEO of Arcturus Therapeutics. “We are also encouraged by the clinical progress of our mRNA therapeutics pipeline, especially the collection of meaningful safety data for CF and OTC deficiency candidates, ARCT-032 and ARCT-810.”
“The aggregate safety data of ARCT-032 and ARCT-810 support continuing clinical development of these rare disease programs,” said Dr. Juergen Froehlich, Chief Medical Officer of Arcturus Therapeutics. “The planned ARCT-032 Phase 2 study advances our efforts to provide a potential treatment for CF patients who have genotypes making them ineligible for modulator treatment and the additional CF population who are eligible but are not prescribed modulators.”
Dr. Froehlich added: “We are also pleased to report that the dosing phase in our European Phase 2 ARCT-810 study is near completion with interim data to be available in Q4. The additional Phase 2 study in the United States has initiated and is designed to expand our OTC deficiency program into more severe and younger patients.”
Recent Corporate Highlights
Financial Results for the three months ended June 30, 2024
Revenues in conjunction with strategic alliances and collaborations
Arcturus’ primary revenue streams include license fees, consulting and related technology transfer fees, reservation fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended June 30, 2024, we reported revenue of $49.9 million, a significant increase of $39.4 million from the $10.5 million reported in the same period in 2023. The increase was primarily due to the CSL agreement during the second quarter of 2024. This increase in CSL revenue recognized was driven by the recognition of Kostaive® manufacturing activities and clinical trial expenses. Additionally, revenue related to the BARDA agreement increased due to advancements in the pandemic flu program.
Revenue decreased by $2.9 million during the six months ended June 30, 2024, as compared to the same period in 2023. The decrease was primarily due to lower CSL revenue resulting from the timing and value of milestone achievements. The overall decrease was offset by higher BARDA revenue due to increased progress of the pandemic flu program.
Operating expenses
Total operating expenses for the three months ended June 30, 2024, were $71.0 million compared with $65.9 million for the three months ended June 30, 2023. Total operating expenses for the six months ended June 30, 2024, were $139.4 million compared with $131.4 million for the six months ended June 30, 2023.
Research and development expenses
Research and development expenses consist primarily of external manufacturing costs, in vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel-related expenses, facility-related expenses and laboratory supplies related to conducting research and development activities. Research and development expenses were $58.7 million for the three months ended June 30, 2024, compared with $52.7 million for the three months ended June 30, 2023. Research and development expenses were $112.2 million for the six months ended June 30, 2024, compared with $104.4 million for the three months ended June 30, 2023. The increases in research and development expenses were primarily driven by higher clinical and manufacturing expenses. Additionally, investments increased in early stage and discovery technologies, including the initiation of preclinical research related to its Gonorrhea and Lyme disease vaccine discovery programs.
General and Administrative Expenses
General and administrative expenses primarily consist of salaries and related benefits for executive, administrative, legal and accounting functions and professional service fees for legal and accounting services as well as other general and administrative expenses. General and administrative expenses were $12.3 million and $27.2 million for the three and six months ended June 30, 2024, respectively, compared with $13.2 million and $27.0 million in the comparable periods last year. These expenses remained relatively consistent between the two periods. The Company does not expect that general and administrative expenses will increase on a yearly basis.
Net Loss
For the three months ended June 30, 2024, Arcturus reported a net loss of approximately $17.2 million, or ($0.64) per diluted share, compared with a net loss of $52.6 million, or ($1.98) per diluted share in the three months ended June 30, 2023. For the six months ended June 30, 2024, Arcturus reported a net loss of approximately $44.0 million, or ($1.64) per diluted share, compared with a net loss of $1.8 million, or ($0.07) per diluted share in the six months ended June 30, 2023.
Cash Position and Balance Sheet
Cash, cash equivalents and restricted cash were $317.2 million as of June 30, 2024, and $348.9 million on December 31, 2023. Arcturus achieved a total of approximately $437.1 million in upfront payments and milestones from CSL as of June 30, 2024, and expects to continue to receive future milestone payments from CSL supporting the ongoing development of the COVID and flu programs and three additional vaccine programs by CSL. The expected cash runway extends approximately three years based on the current pipeline and programs through the first quarter of fiscal year 2027.
Arcturus Therapeutics Second Quarter 2024 Earnings Conference Call
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success and continued advancement of the Company’s pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood of commercialization of Kostaive® and the timing thereof, the continued clinical development of the rare disease programs, the planned completion of the European Phase 2 ARCT-810 Phase 2 study and availability of interim data from the study, the likelihood and timing of a European Marketing Authorization application approval decision for Kostaive®, the anticipated enrollment in the Phase 2 clinical program for ARCT-810, that preclinical or clinical data will be predictive of future clinical results, the likelihood and timing of clinical study updates, the likelihood or timing of collection of accounts receivables including expected future milestone and other payments from CSL, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Trademark Acknowledgements
The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR® and STARR®, are the property of Arcturus. All other trademarks, services marks, and trade names in this announcement are the property of their respective owners.
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
|
| June 30, |
| December 31, | ||||
(in thousands, except par value information) |
| (unaudited) |
|
| ||||
Assets |
|
|
|
| ||||
Current assets: |
|
|
|
| ||||
Cash and cash equivalents |
| $ | 260,329 |
|
| $ | 292,005 |
|
Restricted cash |
|
| 55,000 |
|
|
| 55,000 |
|
Accounts receivable |
|
| 24,085 |
|
|
| 32,064 |
|
Prepaid expenses and other current assets |
|
| 7,594 |
|
|
| 7,521 |
|
Total current assets |
|
| 347,008 |
|
|
| 386,590 |
|
Property and equipment, net |
|
| 11,182 |
|
|
| 12,427 |
|
Operating lease right-of-use assets, net |
|
| 28,533 |
|
|
| 28,500 |
|
Non-current restricted cash |
|
| 1,885 |
|
|
| 1,885 |
|
Total assets |
| $ | 388,608 |
|
| $ | 429,402 |
|
Liabilities and stockholders’ equity |
|
|
|
| ||||
Current liabilities: |
|
|
|
| ||||
Accounts payable |
| $ | 13,905 |
|
| $ | 5,279 |
|
Accrued liabilities |
|
| 35,450 |
|
|
| 31,881 |
|
Deferred revenue |
|
| 42,362 |
|
|
| 44,829 |
|
Total current liabilities |
|
| 91,717 |
|
|
| 81,989 |
|
Deferred revenue, net of current portion |
|
| 11,344 |
|
|
| 42,496 |
|
Operating lease liability, net of current portion |
|
| 26,964 |
|
|
| 25,907 |
|
Other non-current liabilities |
|
| — |
|
|
| 497 |
|
Total liabilities |
|
| 130,025 |
|
|
| 150,889 |
|
Stockholders’ equity |
|
|
|
| ||||
Common stock, $0.001 par value; 60,000 shares authorized; issued and |
|
| 27 |
|
|
| 27 |
|
Additional paid-in capital |
|
| 670,455 |
|
|
| 646,352 |
|
Accumulated deficit |
|
| (411,899 | ) |
|
| (367,866 | ) |
Total stockholders’ equity |
|
| 258,583 |
|
|
| 278,513 |
|
Total liabilities and stockholders’ equity |
| $ | 388,608 |
|
| $ | 429,402 |
|
ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) | ||||||||||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| June 30, |
| June 30, | ||||||||||||
(in thousands, except per share data) |
| 2024 |
| 2023 |
| 2024 |
| 2023 | ||||||||
Revenue: |
|
|
|
|
|
|
|
| ||||||||
Collaboration revenue |
| $ | 45,976 |
|
| $ | 9,565 |
|
| $ | 78,574 |
|
| $ | 89,294 |
|
Grant revenue |
|
| 3,883 |
|
|
| 954 |
|
|
| 9,297 |
|
|
| 1,510 |
|
Total revenue |
|
| 49,859 |
|
|
| 10,519 |
|
|
| 87,871 |
|
|
| 90,804 |
|
Operating expenses: |
|
|
|
|
|
|
|
| ||||||||
Research and development, net |
|
| 58,669 |
|
|
| 52,668 |
|
|
| 112,242 |
|
|
| 104,436 |
|
General and administrative |
|
| 12,316 |
|
|
| 13,225 |
|
|
| 27,167 |
|
|
| 26,987 |
|
Total operating expenses |
|
| 70,985 |
|
|
| 65,893 |
|
|
| 139,409 |
|
|
| 131,423 |
|
Loss from operations |
|
| (21,126 | ) |
|
| (55,374 | ) |
|
| (51,538 | ) |
|
| (40,619 | ) |
(Loss) gain from foreign currency |
|
| (388 | ) |
|
| 149 |
|
|
| (441 | ) |
|
| (179 | ) |
Gain on debt extinguishment |
|
| — |
|
|
| — |
|
|
| — |
|
|
| 33,953 |
|
Finance income, net |
|
| 4,148 |
|
|
| 3,252 |
|
|
| 8,164 |
|
|
| 5,729 |
|
Net loss before income taxes |
|
| (17,366 | ) |
|
| (51,973 | ) |
|
| (43,815 | ) |
|
| (1,116 | ) |
Provision for income taxes |
|
| (150 | ) |
|
| 577 |
|
|
| 218 |
|
|
| 680 |
|
Net loss |
| $ | (17,216 | ) |
| $ | (52,550 | ) |
| $ | (44,033 | ) |
| $ | (1,796 | ) |
Net loss per share, basic and diluted |
| $ | (0.64 | ) |
| $ | (1.98 | ) |
| $ | (1.64 | ) |
| $ | (0.07 | ) |
Weighted-average shares outstanding, basic and diluted |
|
| 26,967 |
|
|
| 26,563 |
|
|
| 26,923 |
|
|
| 26,557 |
|
Comprehensive loss: |
|
|
|
|
|
|
|
| ||||||||
Net loss |
| $ | (17,216 | ) |
| $ | (52,550 | ) |
| $ | (44,033 | ) |
| $ | (1,796 | ) |
Comprehensive loss |
| $ | (17,216 | ) |
| $ | (52,550 | ) |
| $ | (44,033 | ) |
| $ | (1,796 | ) |
Last Trade: | US$16.91 |
Daily Change: | -0.16 -0.94 |
Daily Volume: | 513,147 |
Market Cap: | US$457.250M |
November 11, 2024 November 07, 2024 September 30, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB